Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02765555 · ClinicalTrials.gov registry record · Phase 1
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
A Phase 1 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02765555 is a Phase 1 study that has completed, run by Indivior. The registered enrollment target is 12 participants.
The verdict
NCT02765555, a Phase 1 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and PK profile of a single dose of 60mg RBO-7000 in stable subjects with schizophrenia who are on medication other than risperidone.
Interventions
- DRUG RBP-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02765555
The ClinicalTrials.gov registry entry for NCT02765555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RBP-7000 is the first listed.
NCT02765555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02765555 about?
NCT02765555 is a clinical study titled "First in Man Study of Safety, Tolerability and PK Profile of RBP-7000". The purpose of this study is to assess the safety, tolerability and PK profile of a single dose of 60mg RBO-7000 in stable subjects with schizophrenia who are on medication other than risperidone.
What is the current status of trial NCT02765555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-03. Estimated completion is 2010-09.
What interventions are being tested in trial NCT02765555?
The interventions under investigation include: RBP-7000 (DRUG).
Who is sponsoring clinical trial NCT02765555?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.